Cambria Pharmaceuticals, Inc. Garners $5,400,000 Series A Funding

  • Feed Type
  • Date
  • Company Name
    Cambria Pharmaceuticals, Inc.
  • Mailing Address
    8A Henshaw St Woburn, MA 01801
  • Company Description
    Cambria Pharmaceuticals is focused on the discovery of innovative treatments for serious and progressively disabling neurological disorders. The Company exploits recent discoveries in the genetic basis of these disorders to engineer novel disease models and identify first-in-class, disease-modifying compounds. Cambria leverages collaborative relationships with academic institutions and patient-focused foundations to advance its programs in ALS (Lou Gehrig’s disease) and other serious neurological diseases.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    This investment will be used, along with a comparable amount of venture philanthropy funding that we have previously obtained, to advance our lead program in ALS, as well as drug discovery efforts for other serious neurological disorders,” stated Leo Liu, M.D., President and CEO.
  • M&A Terms
  • Venture Investor
    Biogen Idec Inc.
  • Venture Investor

Trending on Xconomy